-+ 0.00%
-+ 0.00%
-+ 0.00%

Genprex Announces That Its Research Collaborators Presented Positive Preclinical Data And Research From Studies Of Gpx-002 At The 2025 American Diabetes Association 85th Scientific Session In Chicago

Benzinga·06/23/2025 13:04:03
Listen to the news

Novel Diabetes Gene Therapy Shows Potential for Re-Dosing Using Non-Viral Delivery System

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ:GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators presented positive preclinical data and research from studies of GPX-002, the Company's diabetes gene therapy drug candidate, at the 2025 American Diabetes Association (ADA) 85th Scientific Session in Chicago. These studies used an alternative second-generation approach with a non-viral lipid nanoparticle delivery system. This exploratory research represents the Company's forward-thinking work within its diabetes program to determine if the novel diabetes gene therapy can be delivered using a non-viral delivery system which could allow for repeat dosing.